How to Buy GlaxoSmithKline Pharmaceuticals Ltd Shares?
You can easily buy the stocks/shares of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) on Tickertape or through broker platform by opening a Demat & Trading account onlineWhat is the Share Price of GlaxoSmithKline Pharmaceuticals Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of GLAXO as on 15th May 2025 is ₹2880.82What is the return on GlaxoSmithKline Pharmaceuticals Ltd share?
The past returns of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) share are- Past 1 week: N/A
- Past 1 month: -34.67
- Past 3 months: 23.97
- Past 6 months: 46.18
- Past 1 year: 22.01
- Past 3 years: 115.00
- Past 5 years: 137.32
What is the Dividend yield % on GlaxoSmithKline Pharmaceuticals Ltd share?
The current dividend yield of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is 1.64What is the Market Cap of GlaxoSmithKline Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is ₹55745.56Cr as of 15th May 2025What is the 52 Week High and Low of GlaxoSmithKline Pharmaceuticals Ltd?
The 52-week high and low of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is ₹3515.70 and ₹1921.What is the PE and PB ratio of GlaxoSmithKline Pharmaceuticals Ltd?
The P/E (price-to-earnings) and P/B (price-to-book) ratios of GlaxoSmithKline Pharmaceuticals Ltd are 60.10 and 28.57 respectively.Which sector does GlaxoSmithKline Pharmaceuticals Ltd belong to?
GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) belongs to the Health Care sector & Pharmaceuticals sub-sector.What are the peers or stocks similar to GlaxoSmithKline Pharmaceuticals Ltd?
The peers or stocks similar to GlaxoSmithKline Pharmaceuticals Ltd are: and many others.Can't decide whether or not to buy GlaxoSmithKline Pharmaceuticals Ltd?
Worry no more! Login to Tickertape and check out GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) scorecard & all the relevant insights today5. Test Stocks FAQ What is the 52 Week High and Low of GlaxoSmithKline Pharmaceuticals Ltd?
The 52-week high and low of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is ₹3515.70 and ₹1921.1. Test Stocks FAQ for GlaxoSmithKline Pharmaceuticals Ltd Shares?
You can easily buy the stocks/shares of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) on Tickertape or through broker platform by opening a Google & Trading account online3. Test Stocks FAQ What is the Share Price of GlaxoSmithKline Pharmaceuticals Ltd?
The stock prices are volatile and keep changing through the day depending upon various factors and market conditions. The Share price of GLAXO as on 15th May 2025 is ₹2880.82
GlaxoSmithKline Pharmaceuticals Ltd
GLAXO Share Price
2,880.820.07% (+2.02)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
GLAXO Performance & Key Metrics
GLAXO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 60.10 | 28.57 | 1.64% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.21 | 6.66 | 0.83% |
GLAXO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
GLAXO Company Profile
GlaxoSmithKline Pharmaceuticals is a pharmaceutical company engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in pharmaceuticals, vaccines and consumer healthcare.
SUNPHARMA
PE Ratio
37.00
37.00
1Y Return
11.72%
11.72%
Buy Reco %
89.19
89.19
CIPLA
PE Ratio
23.03
23.03
1Y Return
2.55%
2.55%
Buy Reco %
71.05
71.05
DRREDDY
PE Ratio
20.02
20.02
1Y Return
11.76%
11.76%
Buy Reco %
82.05
82.05
TORNTPHARM
PE Ratio
57.53
57.53
1Y Return
13.13%
13.13%
Buy Reco %
67.74
67.74
MANKIND
PE Ratio
49.29
49.29
1Y Return
6.30%
6.30%
Buy Reco %
—
—
GLAXO Sentiment Analysis
GLAXO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
GLAXO Stock Summary · January 2025
Company is navigating a complex landscape characterized by declining market share in deposits, challenges in meeting Priority Sector Lending (PSL) obligations, and fluctuations in current account flows. Despite these hurdles, the bank is focusing on enhancing customer engagement and service delivery to drive deposit growth, with recent monthly inflows showing a positive trend. The management emphasizes a strategic approach to maintaining profitability over aggressive expansion, particularly in light of competitive pressures and a tight liquidity environment. Efforts to improve operational efficiencies through digitization and a commitment to stable cost management are underway, alongside a proactive strategy to reduce borrowings and strengthen the balance sheet. Overall, while facing short-term challenges, the bank remains optimistic about future performance and is committed to achieving sustainable growth through strategic investments and improved customer outreach.
GLAXO Stock Growth Drivers
GLAXO Stock Growth Drivers
3Focus on Sustainable Growth
Company is prioritizing profitable growth over mere expansion, emphasizing a strategy that encourages ground-level teams
Stable Financial Metrics
The company has maintained a return on assets (ROA) of 1.9% post-merger, showcasing stability in
GLAXO Stock Challenges
GLAXO Stock Challenges
1Deposit Growth Shortfalls
The company has experienced deposit growth that has not met expectations, attributed to seasonal trends
GLAXO Forecast
What are forecasts?
What are forecasts?
Forecasting uses historical data as inputs to make informed predictive estimates determining the direction of future trends. Price, revenue & earnings forecasts represent where the stock level, business prospects and profits are potentially expected to be at the end of the forecast period
GLAXO Forecasts
Price
Revenue
Earnings
GLAXO Share Price Forecast
GLAXO Share Price Forecast
2025
Current
₹3,295.00
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹3,295.00
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
GLAXO Company Revenue Forecast
GLAXO Company Revenue Forecast
2025
Current
₹3.90
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹3.90
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
GLAXO Stock EPS (Earnings Per Share) Forecast
GLAXO Stock EPS (Earnings Per Share) Forecast
2025
Current
₹54.76
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹54.76
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
GLAXO
GLAXO
Income
Balance Sheet
Cash Flow
Annual Normal View
GLAXO Income Statement
GLAXO Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,029.71 | 2,943.80 | 3,279.21 | 3,850.20 | 3,143.70 | 4,700.86 | 3,365.83 | 3,595.99 | 3,899.83 | 3,899.83 | ||||||||||
Raw Materials | 1,314.38 | 1,299.24 | 1,332.46 | 1,343.30 | 1,294.88 | 1,340.62 | 1,215.92 | 1,398.25 | 1,345.00 | 2,571.85 | ||||||||||
| Power & Fuel Cost | 27.82 | 26.44 | 27.94 | 33.36 | 26.08 | 27.83 | 29.60 | 29.64 | 30.18 | |||||||||||
| Employee Cost | 483.01 | 523.40 | 537.20 | 628.55 | 616.16 | 610.23 | 594.99 | 624.39 | 579.70 | |||||||||||
| Selling & Administrative Expenses | 373.99 | 358.84 | 381.41 | 376.88 | 242.05 | 343.67 | 370.30 | 374.73 | 383.98 | |||||||||||
| Operating & Other expenses | 292.00 | 157.73 | 268.39 | 1,073.35 | 357.54 | 215.32 | 248.00 | 281.31 | 232.98 | |||||||||||
EBITDA | 538.51 | 578.15 | 731.81 | 394.76 | 606.99 | 2,163.19 | 907.02 | 887.67 | 1,327.99 | 1,327.98 | ||||||||||
| Depreciation/Amortization | 27.08 | 37.99 | 48.59 | 82.68 | 78.60 | 68.19 | 65.77 | 69.68 | 66.79 | 66.79 | ||||||||||
| PBIT | 511.43 | 540.16 | 683.22 | 312.08 | 528.39 | 2,095.00 | 841.25 | 817.99 | 1,261.20 | 1,261.19 | ||||||||||
| Interest & Other Items | 0.25 | 0.19 | 0.55 | 6.34 | 3.53 | 2.00 | 1.81 | 1.80 | 1.31 | 1.31 | ||||||||||
| PBT | 511.18 | 539.97 | 682.67 | 305.74 | 524.86 | 2,093.00 | 839.44 | 816.19 | 1,259.89 | 1,259.88 | ||||||||||
| Taxes & Other Items | 174.38 | 189.24 | 237.27 | 212.55 | 166.72 | 398.28 | 228.76 | 226.23 | 332.30 | 332.30 | ||||||||||
| Net Income | 336.80 | 350.73 | 445.40 | 93.19 | 358.14 | 1,694.72 | 610.68 | 589.96 | 927.59 | 927.58 | ||||||||||
| EPS | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 54.76 | 54.75 | ||||||||||
| DPS | 15.00 | 17.50 | 20.00 | 40.00 | 30.00 | 90.00 | 32.00 | 32.00 | 54.00 | 12.00 | ||||||||||
| Payout ratio | 0.75 | 0.85 | 0.76 | 7.27 | 1.42 | 0.90 | 0.89 | 0.92 | 0.99 | 0.22 |
GLAXO Company Updates
GLAXO Stock Peers
What are peers and why compare against them?
What are peers and why compare against them?
A stock's peers are companies which have similar business interests, operations and belong to the same industry sector. Comparing various metrics against peers can give valuable insights on whether the company's stock is over/under-valued and the company's growth outlook vs the industry as a whole
GLAXO Past Performance & Peer Comparison
GLAXO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd | 60.10 | 28.57 | 1.64% |
| Sun Pharmaceutical Industries Ltd | 37.00 | 6.03 | 0.95% |
| Cipla Ltd | 23.03 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.02 | 4.01 | 0.59% |
GLAXO Stock Price Comparison
Compare GLAXO with any stock or ETFCompare GLAXO with any stock or ETF
GLAXO
GLAXO Holdings
GLAXO Shareholdings
What are shareholdings?
What are shareholdings?
Apart from retail investors, a company’s shares are held by promoters, foreign & domestic institutions (large investors) and mutual funds. Promoters are the ship captains and control the company’s direction. Along with institutional and mutual fund holdings, a change in their holdings can indicate performance outlook for the stock
GLAXO Promoter Holdings Trend
GLAXO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
GLAXO Institutional Holdings Trend
GLAXO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
GLAXO Shareholding Pattern
GLAXO Shareholding Pattern
GLAXO Shareholding History
GLAXO Shareholding History
Foreign Institutions
Mutual Funds Invested in GLAXO
Mutual Funds Invested in GLAXO
No mutual funds holding trends are available
Top 5 Mutual Funds holding GlaxoSmithKline Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9025% | Percentage of the fund’s portfolio invested in the stock 2.34% | Change in the portfolio weight of the stock over the last 3 months 2.34% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/63 (+3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5522% | Percentage of the fund’s portfolio invested in the stock 3.73% | Change in the portfolio weight of the stock over the last 3 months 0.45% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 8/40 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5169% | Percentage of the fund’s portfolio invested in the stock 1.87% | Change in the portfolio weight of the stock over the last 3 months 1.87% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/67 (-3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing GLAXO stock
smallcases containing GLAXO stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have GlaxoSmithKline Pharmaceuticals Ltd
GLAXO Events
GLAXO Events
GLAXO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
GLAXO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.64%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹16.41 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
What are dividends?
What are dividends?
Dividends are a portion of earnings that a company distributes to all its shareholders every year. Dividend return is one of the most important things to be considered while investing for long term. It’s the additional return on top of what investors earn through price appreciation
GLAXO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
GLAXO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 1.64%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹16.41 every year
GLAXO Upcoming Dividends
GLAXO Upcoming Dividends
No upcoming dividends are available
GLAXO Past Dividends
GLAXO Past Dividends
Cash Dividend
Ex DateEx DateMay 30, 2025
Final
Final | Div/Share: ₹42.00
Dividend/Share
₹42.00
Ex DateEx Date
May 30, 2025
Cash Dividend
Ex DateEx DateNov 7, 2024
Special
Special | Div/Share: ₹12.00
Dividend/Share
₹12.00
Ex DateEx Date
Nov 7, 2024
Cash Dividend
Ex DateEx DateJul 7, 2022
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Jul 7, 2022
Cash Dividend
Ex DateEx DateJul 7, 2022
Special
Special | Div/Share: ₹60.00
Dividend/Share
₹60.00
Ex DateEx Date
Jul 7, 2022
Cash Dividend
Ex DateEx DateJul 19, 2021
Final
Final | Div/Share: ₹30.00
Dividend/Share
₹30.00
Ex DateEx Date
Jul 19, 2021
GLAXO Stock News & Opinions
GLAXO Stock News & Opinions
Articles & Videos
Corporate
GlaxoSmithKline Pharmaceuticals fixes record date for final dividend
GlaxoSmithKline Pharmaceuticals has fixed 30 May 2025 as record date for determining entitlement of members to final dividend for the financial year ended 31st March 2025. The dividend, if approved, shall be paid on or after 30 June 2025. Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
GSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/share
Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses declined 3.53% YoY to Rs 650.64 crore. Notably, the cost of materials consumed dropped 43.65% YoY to Rs 108.35 crore, while employee benefits expense fell 11.49% to Rs 152.97 crore. On a full-year basis, the company's net profit jumped 57.19% to Rs 919.06 crore on a 9.28% rise in revenue to Rs 3,723.49 crore in FY25 over FY24. Bhushan Akshikar, managing director of GlaxoSmithKline Pharmaceuticals, said, 'Our diversified portfolio of general medicines, specialty, and vaccines has shown improved growth due to sustained innovation, enhanced healthcare professional (HCP) engagement, and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.' The company said it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (Dostarlimab), an immunotherapy for second-line treatment of endometrial cancer. Meanwhile, the board recommended a final dividend of Rs 42 per equity share for FY25, subject to shareholder approval at the company's 100th Annual General Meeting. GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Glaxosmithkline Pharmaceuticals consolidated net profit rises 35.17% in the March 2025 quarter
Net profit of Glaxosmithkline Pharmaceuticals rose 35.17% to Rs 262.87 crore in the quarter ended March 2025 as against Rs 194.48 crore during the previous quarter ended March 2024. Sales rose 4.79% to Rs 974.37 crore in the quarter ended March 2025 as against Rs 929.80 crore during the previous quarter ended March 2024. For the full year,net profit rose 57.23% to Rs 927.58 crore in the year ended March 2025 as against Rs 589.96 crore during the previous year ended March 2024. Sales rose 8.56% to Rs 3749.21 crore in the year ended March 2025 as against Rs 3453.71 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales974.37929.80 5 3749.213453.71 9 OPM %34.2027.67 -31.4026.31 - PBDT373.29286.32 30 1321.981029.48 28 PBT358.57268.22 34 1255.19959.80 31 NP262.87194.48 35 927.58589.96 57 Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Glaxosmithkline Pharmaceuticals standalone net profit rises 34.73% in the March 2025 quarter
Net profit of Glaxosmithkline Pharmaceuticals rose 34.73% to Rs 260.14 crore in the quarter ended March 2025 as against Rs 193.08 crore during the previous quarter ended March 2024. Sales rose 6.06% to Rs 966.08 crore in the quarter ended March 2025 as against Rs 910.87 crore during the previous quarter ended March 2024. For the full year,net profit rose 57.19% to Rs 919.06 crore in the year ended March 2025 as against Rs 584.69 crore during the previous year ended March 2024. Sales rose 9.28% to Rs 3723.49 crore in the year ended March 2025 as against Rs 3407.25 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales966.08910.87 6 3723.493407.25 9 OPM %34.2428.03 -31.4026.43 - PBDT369.62284.41 30 1310.541022.33 28 PBT354.90266.31 33 1243.75952.65 31 NP260.14193.08 35 919.06584.69 57 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
GlaxoSmithKline Pharmaceuticals to conduct board meeting
GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Glaxosmithkline Pharmaceuticals consolidated net profit rises 402.80% in the December 2024 quarter
Net profit of Glaxosmithkline Pharmaceuticals rose 402.80% to Rs 229.88 crore in the quarter ended December 2024 as against Rs 45.72 crore during the previous quarter ended December 2023. Sales rose 17.90% to Rs 949.42 crore in the quarter ended December 2024 as against Rs 805.26 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales949.42805.26 18 OPM %30.7527.08 - PBDT326.90245.85 33 PBT308.10228.74 35 NP229.8845.72 403 Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Glaxosmithkline Pharmaceuticals Ltd leads gainers in 'A' group
Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmalabs Ltd are among the other gainers in the BSE's 'A' group today, 06 February 2025.Glaxosmithkline Pharmaceuticals Ltd soared 7.88% to Rs 2148.8 at 11:48 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 8603 shares were traded on the counter so far as against the average daily volumes of 4008 shares in the past one month. Spandana Sphoorty Financial Ltd spiked 7.44% to Rs 351.75. The stock was the second biggest gainer in 'A' group. On the BSE, 50402 shares were traded on the counter so far as against the average daily volumes of 1.73 lakh shares in the past one month. Reliance Power Ltd surged 7.07% to Rs 42.71. The stock was the third biggest gainer in 'A' group. On the BSE, 66.83 lakh shares were traded on the counter so far as against the average daily volumes of 32.11 lakh shares in the past one month. Fusion Finance Ltd rose 6.35% to Rs 185.8. The stock was the fourth biggest gainer in 'A' group. On the BSE, 40400 shares were traded on the counter so far as against the average daily volumes of 39721 shares in the past one month. Aarti Pharmalabs Ltd gained 6.34% to Rs 678. The stock was the fifth biggest gainer in 'A' group. On the BSE, 3.11 lakh shares were traded on the counter so far as against the average daily volumes of 25140 shares in the past one month. Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
GlaxoSmithKline Pharmaceuticals revises board meeting date
GlaxoSmithKline Pharmaceuticals has revised the meeting of the Board of Directors which was scheduled to be held on 10 February 2025. The meeting will now be held on 14 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
GlaxoSmithKline Pharmaceuticals declare Quarterly Result
GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Glaxosmithkline Pharmaceuticals consolidated net profit rises 16.09% in the September 2024 quarter
Net profit of Glaxosmithkline Pharmaceuticals rose 16.09% to Rs 252.50 crore in the quarter ended September 2024 as against Rs 217.51 crore during the previous quarter ended September 2023. Sales rose 5.62% to Rs 1010.77 crore in the quarter ended September 2024 as against Rs 956.99 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1010.77956.99 6 OPM %31.8330.25 - PBDT355.98317.27 12 PBT339.12299.16 13 NP252.50217.51 16 Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 1.86%, vs industry avg of 9.02%
Over the last 5 years, market share increased from 0.8% to 0.94%
Over the last 5 years, net income has grown at a yearly rate of 5.78%, vs industry avg of 15.29%